Skip to Main Content

Author Details

Davide Prandi
University of Trento
2009
28
18
PMIDPaper TitleJournal TitlePublished Year
34731645Allele-specific genomic data elucidate the role of somatic gain and copy-number neutral loss of heterozygosity in cancer.Cell Syst2022
34731645Allele-specific genomic data elucidate the role of somatic gain and copy-number neutral loss of heterozygosity in cancer.Cell Syst2022
35220606Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.J Pathol2022
35220606Comparative genomics of primary prostate cancer and paired metastases: insights from 12 molecular case studies.J Pathol2022
33998599Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.J Clin Invest2021
33998599Tumor subtype defines distinct pathways of molecular and clinical progression in primary prostate cancer.J Clin Invest2021
33015524Systematic Assessment of Tumor Purity and Its Clinical Implications.JCO Precis Oncol2020
33144576Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.Nat Commun2020
33015524Systematic Assessment of Tumor Purity and Its Clinical Implications.JCO Precis Oncol2020
33144576Role of specialized composition of SWI/SNF complexes in prostate cancer lineage plasticity.Nat Commun2020
31061129Genomic correlates of clinical outcome in advanced prostate cancer.Proc Natl Acad Sci U S A2019
30232224A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.Clin Cancer Res2019
31524989Ploidy- and Purity-Adjusted Allele-Specific DNA Analysis Using CLONETv2.Curr Protoc Bioinformatics2019
31387980Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues.Proc Natl Acad Sci U S A2019
31061129Genomic correlates of clinical outcome in advanced prostate cancer.Proc Natl Acad Sci U S A2019
31099386TPES: tumor purity estimation from SNVs.Bioinformatics2019
30232224A Phase II Trial of the Aurora Kinase A Inhibitor Alisertib for Patients with Castration-resistant and Neuroendocrine Prostate Cancer: Efficacy and Biomarkers.Clin Cancer Res2019
31387980Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues.Proc Natl Acad Sci U S A2019
31524989Ploidy- and Purity-Adjusted Allele-Specific DNA Analysis Using CLONETv2.Curr Protoc Bioinformatics2019
31099386TPES: tumor purity estimation from SNVs.Bioinformatics2019
29431739A highly specific SpCas9 variant is identified by in vivo screening in yeast.Nat Biotechnol2018
29921838Patient derived organoids to model rare prostate cancer phenotypes.Nat Commun2018
29431739A highly specific SpCas9 variant is identified by in vivo screening in yeast.Nat Biotechnol2018
29921838Patient derived organoids to model rare prostate cancer phenotypes.Nat Commun2018
28059768SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.Science2017
28464947Erratum to: Unraveling the clonal hierarchy of somatic genomic aberrations.Genome Biol2017
28331002Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.Cancer Discov2017
28530235Hit and go CAS9 delivered through a lentiviral based self-limiting circuit.Nat Commun2017
29333526Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.JCO Precis Oncol2017
28059768SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer.Science2017
28464947Erratum to: Unraveling the clonal hierarchy of somatic genomic aberrations.Genome Biol2017
28331002Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.Cancer Discov2017
29333526Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.JCO Precis Oncol2017
28530235Hit and go CAS9 delivered through a lentiviral based self-limiting circuit.Nat Commun2017
26855148Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.Nat Med2016
26855148Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.Nat Med2016
27749842Clonal evolution of chemotherapy-resistant urothelial carcinoma.Nat Genet2016
27749842Clonal evolution of chemotherapy-resistant urothelial carcinoma.Nat Genet2016
25889339ASEQ: fast allele-specific studies from next-generation sequencing data.BMC Med Genomics2015
25889339ASEQ: fast allele-specific studies from next-generation sequencing data.BMC Med Genomics2015
26181256Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.JAMA Oncol2015
26374986SPOP mutation leads to genomic instability in prostate cancer.Elife2015
26374986SPOP mutation leads to genomic instability in prostate cancer.Elife2015
26181256Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.JAMA Oncol2015
25160065Unraveling the clonal hierarchy of somatic genomic aberrations.Genome Biol2014
25232177Tumor clone dynamics in lethal prostate cancer.Sci Transl Med2014
25160065Unraveling the clonal hierarchy of somatic genomic aberrations.Genome Biol2014
25232177Tumor clone dynamics in lethal prostate cancer.Sci Transl Med2014
23622249Punctuated evolution of prostate cancer genomes.Cell2013
23622249Punctuated evolution of prostate cancer genomes.Cell2013
  • 1 - 50 of 56

Recommended Authors

University of California los angeles
Career Start Year 2015
Number of shared co-authors 5
Institute for Cancer Research, Oslo University Hospital
Career Start Year 2014
Number of shared co-authors 7
Princess Margaret Cancer Centre
Career Start Year 2012
Number of shared co-authors 5
Human Longevity Inc.
Career Start Year 2012
Number of shared co-authors 4
The Hospital for Sick Children
Career Start Year 2012
Number of shared co-authors 5
University of British Columbia
Career Start Year 2011
Number of shared co-authors 16
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 9
Universita del Piemonte Orientale
Career Start Year 2010
Number of shared co-authors 1
Memorial Sloan Kettering Cancer Center
Career Start Year 2010
Number of shared co-authors 18
CRUK Cambridge Institute, University of Cambridge
Career Start Year 2009
Number of shared co-authors 0
University of Lausanne (UNIL)
Career Start Year 2008
Number of shared co-authors 15
Broad Institute of Massachusetts Institute of Technology and Harvard
Career Start Year 2008
Number of shared co-authors 13
University of Texas MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 11
Greehey Children's Cancer Research Institute
Career Start Year 2007
Number of shared co-authors 12
German Cancer Research Centre DKFZ
Career Start Year 2007
Number of shared co-authors 0
Memorial Sloan Kettering Cancer Center
Career Start Year 2006
Number of shared co-authors 40
Prostate Cancer Research Center, Tampere University and Tays Cancer Center
Career Start Year 2006
Number of shared co-authors 14
Manchester Cancer Research Centre, University of Manchester
Career Start Year 2006
Number of shared co-authors 5
Novartis Institutes for BioMedical Research
Career Start Year 2005
Number of shared co-authors 8
University of Copenhagen
Career Start Year 2004
Number of shared co-authors 9
Stanford University School of Medicine
Career Start Year 2004
Number of shared co-authors 1
Princess Margaret Cancer Centre, University Health Network
Career Start Year 2003
Number of shared co-authors 19
University of Texas MD Anderson Cancer Center
Career Start Year 2003
Number of shared co-authors 13
The Francis Crick Institute
Career Start Year 2003
Number of shared co-authors 5
University of California
Career Start Year 2003
Number of shared co-authors 0
Memorial Sloan Kettering Cancer Center
Career Start Year 2003
Number of shared co-authors 5
Wellcome Sanger Institute
Career Start Year 2003
Number of shared co-authors 9
Monash University
Career Start Year 2000
Number of shared co-authors 4
Francis Crick Institute
Career Start Year 1997
Number of shared co-authors 16
McDonnell Genome Institute, Washington University School of Medicine
Career Start Year 1997
Number of shared co-authors 17

Collaborators

University of Trento
Co-authored papers 25
University of Bern
Co-authored papers 16
Institute for Computational Biomedicine
Co-authored papers 16
Dana-Farber Cancer Institute
Co-authored papers 15
Caryl and Israel Englander Institute for Precision Medicine
Co-authored papers 12
University of Trento
Co-authored papers 9
Meyer Cancer Center
Co-authored papers 8
Paris Sciences Lettres University PSL, Institut CURIE
Co-authored papers 6
Sandra and Edward Meyer Cancer Center
Co-authored papers 6
Weill Cornell Medical College
Co-authored papers 6
Sandra and Edward Meyer Cancer Center
Co-authored papers 6
Meyer Cancer Center, Weill Cornell Medicine-NewYork Presbyterian Hospital
Co-authored papers 6
Sandra and Edward Meyer Cancer Center
Co-authored papers 5
Sandra and Edward Meyer Cancer Center
Co-authored papers 5
Broad Institute of Harvard and MIT
Co-authored papers 4
Institut Curie, CNRS, PSL Research University
Co-authored papers 4
Institute for Pathology, University Hospital Schleswig-Holstein
Co-authored papers 4
University Hospital Zurich
Co-authored papers 4
Case Western Reserve University
Co-authored papers 4
Memorial Sloan Kettering Cancer Center
Co-authored papers 3
Co-authored papers 3
INSERM, Universite Clermont Auvergne
Co-authored papers 3
Co-authored papers 3
The Institute for Cancer Research
Co-authored papers 3
Dana-Farber Cancer Institute
Co-authored papers 3
Montefiore Medical Center/Albert Einstein College of Medicine
Co-authored papers 3
Rogel Cancer Center, University of Michigan Medical School ann arbor
Co-authored papers 3
New York University Langone Health
Co-authored papers 3
Variant Bio Inc.
Co-authored papers 2
Michigan Center for Translational Pathology, University of Michigan ann arbor
Co-authored papers 2